Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Iranian Journal of Cancer Prevention. 2010; 3 (4): 174-177
in English | IMEMR | ID: emr-99205

ABSTRACT

The aim of this study was to evaluate over expression of epidermal growth factor receptor [EGFR] gene in localized prostate cancers and determine its relation with clinical and pathological factors affecting the progression of the disease. In the tissue samples of the patients with prostate cancer undergoing radical prostatectomy, EGFR expression was evaluated by immunohistochemistry technique. Those with scores 2 and 3 were considered to be positive for the expression. The relation between gene expression and grade was evaluated by chi-square test. Of 100 tissue samples evaluated, 80 and 20 had Gleason score [GS] < 7 and >/= 7, respectively. Also, 68 and 32 had PSA level 10, respectively. A total of 59 samples were positive for EGFR expression, of whom, 46 had GS < 7 and 13 had GS > 7 [P-value = 0.39]. Forty patients had PSA < 10 and 19 had PSA > 10 [P-value = 0.5]. Fifty-nine percent of the patients with localized prostate cancer undergoing radical prostatectomy were EGFR positive. No significant relation was found between EGFR and grading [GS] or PSA

2.
Iranian Journal of Cancer Prevention. 2008; 1 (3): 91-93
in English | IMEMR | ID: emr-87017

ABSTRACT

Tamoxifen, a synthetic anti-estrogen agent, is administered as an adjuvant treatment in breast cancer. Since various studies have indicated that Tamoxifen can change some hormones and bound globolines, controversial results have been achieved using this medicine on Thyroid Functional Tests [TFT]. The present study was conducted to investigate the effects of Tamoxifen on TFT in women with breast cancer referred to oncology clinic in Imam Hossein hospital between 2001 and 2002. A quasi-experimental clinical trial study was performed on 23 women with breast cancer in a single blind basis [with no control group]. Patients were under Tamoxifen 20 mg P.O. daily and their serum TSH, free T4 and three Iodothyronine [T3] were assessed before treatment with Tamoxifen and after 3 months. Paired T test was used for statistical analysis. There was a significant difference in T3 before and after the treatment with Tamoxifen [p = 0.02], whereas no significant differences were seen in TSH [p = 0.095] and FT4 [p = 0.13]. This study showed that treatment with Tamoxifen in women suffering from breast cancer results in an increase in serum T3 but has no effect on serum TSH and FT4, therefore women under treatment with Tamoxifen remain euthyroid


Subject(s)
Humans , Female , Breast Neoplasms , Tamoxifen/adverse effects
3.
Iranian Journal of Cancer Prevention. 2008; 1 (2): 69-71
in English | IMEMR | ID: emr-143333

ABSTRACT

Currently, cancers are among the important and main problems of health system in Iran and around the world. In young men under 20 to 35 years of age, malignant masses of testis are the most common tumours. The main pathologic feature of these masses is germ cell tumour and about half of them are seminoma. Since seminoma is very prevalent in the forth decade, being affected with this tumour leads to losing many years of healthy life. In a cross sectional study, investigating 139 records of patients with testis tumour revealed 61 patients with stage-1 seminoma. Thirty three patients underwent para-aortic and unilateral pelvic irradiation [54%] while 28 patients only underwent para-aortic irradiation [46%]. The administered radiotherapy dosage varied between 25-40 Gy Mean age of the patients was 37.8 of whom the youngest was 15 and the oldest was 64 years of age. Only one recurrent patient was seen in this cohort who was in para-aortic group. There was no significant difference in recurrence rate between the two radiotherapy methods. [p= 0.7]. Considering fewer complications of para-aortic irradiation and the insignificant difference in the recurrence rate between the two methods of radiotherapy, para-aortic method could be more appropriate and acceptable in the treatment of testicular cancer


Subject(s)
Humans , Male , Recurrence , Cross-Sectional Studies , Neoplasm Staging , Seminoma/radiotherapy , Germ Cells , Testicular Neoplasms
SELECTION OF CITATIONS
SEARCH DETAIL